Syndax Pharmaceuticals
SNDX
83 hedge funds and large institutions have $228M invested in Syndax Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 11 closing their positions.
2,657% more call options, than puts
Call options by funds: $6.23M | Put options by funds: $226K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
56% more capital invested
Capital invested by funds: $146M → $228M (+$81.4M)
15% more funds holding
Funds holding: 72 → 83 (+11)
7.23% more ownership
Funds ownership: 61.44% → 68.67% (+7.2%)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$9.3M |
| 2 |
ACM
Aisling Capital Management
New York
|
+$8.21M |
| 3 |
BlackRock
New York
|
+$6.51M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$4.46M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.35M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$901K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$582K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$464K |
| 5 |
Goldman Sachs
New York
|
-$435K |
SNDX Hedge Fund Activity: Q1 2020 in Review
83 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2020, worth a combined $228M — up 56% from $146M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SNDX positions and 11 closed out — a net gain of 11 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $9.3M. The largest seller was Adage Capital Partners, cutting an estimated $2.35M.
- 83 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2020, up from 72 in Q4 2019.
- Funds reported $228M of Syndax Pharmaceuticals stock for Q1 2020, up 56% quarter-over-quarter.
- 22 funds opened new Syndax Pharmaceuticals positions in Q1 2020 and 11 closed out, a net change of +11 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2020 was Frazier Management, an estimated $9.3M added.
- The largest Syndax Pharmaceuticals seller in Q1 2020 was Adage Capital Partners, an estimated $2.35M sold.
Based on aggregated 13F filings for Q1 2020.